Timothy S. Olson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Timothy S. Olson has a total of 401 co-authors. Here are the top co-authors by number of shared publications:
- Daria V. Babushok
Department of Medicine, Division of Hematology‐Oncology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
6 shared publications Monica Bessler
Hospital of the University of Pennsylvania
6 shared publications- Caitlin W. Elgarten
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
4 shared publications Carrie L. Kitko
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
4 shared publications- Elizabeth O. Hexner
University of Pennsylvania
4 shared publications - Nora M. Gibson
Cell Therapy and Transplant Section, Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA
4 shared publications
Latest Publications
- 28 October 2026
- Published by American Society of Hematology in Blood
Low Incidence of Cryptic Genetic Marrow Failure in Pediatric Severe Aplastic Anemia Following Negative Clinical Workup
Distinguishing inherited bone marrow failure syndromes (IBMFS) from acquired idiopathic severe aplastic anemia (SAA) impacts treatment decisions and long-term management. The diagnostic evaluation of SAA has evolved with advances in our understanding of IBMFS. The benefit of germline genetic testing to screen for IBMFS in the context of current comprehensive SAA evaluations has not been systematically assessed. Awaiting genetic testing can delay treatment for idiopathic SAA increasing the risk of life-threatening complications. This retrospective study investigates the incidence of cryptic IBMFS among pediatric patients with SAA evaluated with current standard-of-care clinical and laboratory assessments. Enhanced whole exome sequencing tailored to IBMFS genes was conducted for 153 patients with SAA. Comprehensive clinical and laboratory diagnostic data were available for 149 patients. No clinical or laboratory features of an IBMFS were identified in 113 patients (75.8%) and none harbored pathogenic or likely pathogenic variants diagnostic of IBMFS. At least one clinical finding suggestive of an IBMFS was identified in the remaining 36 patients (24.2%). Of these, one harbored a heterozygous pathogenic variant in SAMD9L and had a consistent clinical history. A second patient flagged by clinical evaluation had two pathogenic variants in ERCC6L2, although allelic phasing and therefore affected status could not be determined. For patients with a negative comprehensive workup for SAA utilizing current diagnostic clinical and laboratory evaluations, the risk of a cryptic IBMFS is low. For these patients, the low likelihood of benefit gained by awaiting genetic testing results must be weighed against the risks of treatment delay.
- 28 October 2026
- Published by American Society of Hematology in Blood
Low Incidence of Cryptic Genetic Marrow Failure in Pediatric Severe Aplastic Anemia Following Negative Clinical Workup
Distinguishing inherited bone marrow failure syndromes (IBMFS) from acquired idiopathic severe aplastic anemia (SAA) impacts treatment decisions and long-term management. The diagnostic evaluation of SAA has evolved with advances in our understanding of IBMFS. The benefit of germline genetic testing to screen for IBMFS in the context of current comprehensive SAA evaluations has not been systematically assessed. Awaiting genetic testing can delay treatment for idiopathic SAA increasing the risk of life-threatening complications. This retrospective study investigates the incidence of cryptic IBMFS among pediatric patients with SAA evaluated with current standard-of-care clinical and laboratory assessments. Enhanced whole exome sequencing tailored to IBMFS genes was conducted for 153 patients with SAA. Comprehensive clinical and laboratory diagnostic data were available for 149 patients. No clinical or laboratory features of an IBMFS were identified in 113 patients (75.8%) and none harbored pathogenic or likely pathogenic variants diagnostic of IBMFS. At least one clinical finding suggestive of an IBMFS was identified in the remaining 36 patients (24.2%). Of these, one harbored a heterozygous pathogenic variant in SAMD9L and had a consistent clinical history. A second patient flagged by clinical evaluation had two pathogenic variants in ERCC6L2, although allelic phasing and therefore affected status could not be determined. For patients with a negative comprehensive workup for SAA utilizing current diagnostic clinical and laboratory evaluations, the risk of a cryptic IBMFS is low. For these patients, the low likelihood of benefit gained by awaiting genetic testing results must be weighed against the risks of treatment delay.
- 25 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6564-6566
Democratizing cancer risk testing in children before alloHCT
- 25 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6564-6566
Democratizing cancer risk testing in children before alloHCT
- 17 July 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1499.e1-1499.e9
Prospective Validation of Multiweek Inpatient Census Forecasting for Pediatric HSCT and Cellular Therapy
- 17 July 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1499.e1-1499.e9
Prospective Validation of Multiweek Inpatient Census Forecasting for Pediatric HSCT and Cellular Therapy
- 7 July 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70271
Invasive Pneumococcal Disease After Hematopoietic Cell Transplantation for Sickle Cell Disease
Background: Children with sickle cell disease (SCD) remain at risk for invasive pneumococcal disease (IPD) because of impaired splenic function and increased susceptibility to encapsulated bacteria. Data describing IPD after allogeneic hematopoietic cell transplantation (HCT) for SCD are limited. Methods: We conducted a multicenter retrospective cohort study of children and young adults with SCD undergoing first allogeneic HCT at two participating Sickle Cell Transplant Advocacy and Research (STAR) centers. IPD occurring within 365 days after HCT was identified through registry data, microbiologic culture review, and supplemental chart review. Results: Among 182 patients undergoing HCT, three developed IPD within the first year after transplant. All cases presented with sepsis and bacteremia; one patient also developed meningitis and died of septic shock. IPD occurred between 7 and 365 days after HCT. None of the patients had received post‐transplant pneumococcal vaccination before IPD diagnosis. Serotype data were unavailable for all cases. Conclusion: In this multicenter cohort of patients with SCD undergoing allogeneic HCT, IPD was uncommon but clinically severe, including late infections occurring nearly one year after transplantation. Prospective studies evaluating immune recovery, splenic function, pneumococcal vaccination practices, and long‐term infectious outcomes are needed to better define persistent susceptibility to invasive pneumococcal disease after HCT in patients with SCD. image
- 7 July 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (5) , e70271
Invasive Pneumococcal Disease After Hematopoietic Cell Transplantation for Sickle Cell Disease
Background: Children with sickle cell disease (SCD) remain at risk for invasive pneumococcal disease (IPD) because of impaired splenic function and increased susceptibility to encapsulated bacteria. Data describing IPD after allogeneic hematopoietic cell transplantation (HCT) for SCD are limited. Methods: We conducted a multicenter retrospective cohort study of children and young adults with SCD undergoing first allogeneic HCT at two participating Sickle Cell Transplant Advocacy and Research (STAR) centers. IPD occurring within 365 days after HCT was identified through registry data, microbiologic culture review, and supplemental chart review. Results: Among 182 patients undergoing HCT, three developed IPD within the first year after transplant. All cases presented with sepsis and bacteremia; one patient also developed meningitis and died of septic shock. IPD occurred between 7 and 365 days after HCT. None of the patients had received post‐transplant pneumococcal vaccination before IPD diagnosis. Serotype data were unavailable for all cases. Conclusion: In this multicenter cohort of patients with SCD undergoing allogeneic HCT, IPD was uncommon but clinically severe, including late infections occurring nearly one year after transplantation. Prospective studies evaluating immune recovery, splenic function, pneumococcal vaccination practices, and long‐term infectious outcomes are needed to better define persistent susceptibility to invasive pneumococcal disease after HCT in patients with SCD. image
- Open Access
- 13 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3324-3334
Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders
Children with nonmalignant hematological disorders (NMHD) often require numerous red blood cell transfusions before hematopoietic stem cell transplantation (HSCT), leading to iron overload. Ferritin and liver iron concentration (LIC) are used to estimate the degree of iron overload to determine eligibility for HSCT, but neither marker has been definitively associated with poorer HSCT outcomes in pediatric cohorts. We conducted a multicenter retrospective cohort study using PEDSnet to examine the association between elevated pre-HSCT ferritin and LIC and HSCT outcomes and to evaluate iron reduction therapy after transplantation. A total of 580 patients with a pre-HSCT ferritin and 260 patients with a pre-HSCT LIC were studied. Patients with high pre-HSCT ferritin of >2500 ng/mL had decreased 3-year overall survival (adjusted hazard ratio [HR], 2.31; 95% confidence interval [CI], 1.06-5.04). A sensitivity analysis demonstrated this trend only in patients with severe aplastic anemia (SAA). Elevated ferritin was associated with a markedly increased risk of bacteremia after HSCT in patients with SAA (HR, 3.33; 95% CI, 1.72-6.44). Elevated pre-HSCT LIC of >5 mg Fe/g dry weight was not associated with decreased survival, bacteremia, graft failure, or veno-occlusive disease (VOD). VOD was assessed only in patients undergoing busulfan-based transplantation. After transplantation, 63% of patients in the multicenter analysis had an elevated ferritin, whereas 68% had an elevated LIC. Chelation and phlebotomy were equally effective in reducing post-HSCT iron. These results challenge the use of LIC as the gold standard for iron-related risk stratification in HSCT. Further research into peri-HSCT iron management is necessary in an era of expanding availability of HSCT for NMHD.
- 13 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3324-3334
Open AccessImpact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders
Children with nonmalignant hematological disorders (NMHD) often require numerous red blood cell transfusions before hematopoietic stem cell transplantation (HSCT), leading to iron overload. Ferritin and liver iron concentration (LIC) are used to estimate the degree of iron overload to determine eligibility for HSCT, but neither marker has been definitively associated with poorer HSCT outcomes in pediatric cohorts. We conducted a multicenter retrospective cohort study using PEDSnet to examine the association between elevated pre-HSCT ferritin and LIC and HSCT outcomes and to evaluate iron reduction therapy after transplantation. A total of 580 patients with a pre-HSCT ferritin and 260 patients with a pre-HSCT LIC were studied. Patients with high pre-HSCT ferritin of >2500 ng/mL had decreased 3-year overall survival (adjusted hazard ratio [HR], 2.31; 95% confidence interval [CI], 1.06-5.04). A sensitivity analysis demonstrated this trend only in patients with severe aplastic anemia (SAA). Elevated ferritin was associated with a markedly increased risk of bacteremia after HSCT in patients with SAA (HR, 3.33; 95% CI, 1.72-6.44). Elevated pre-HSCT LIC of >5 mg Fe/g dry weight was not associated with decreased survival, bacteremia, graft failure, or veno-occlusive disease (VOD). VOD was assessed only in patients undergoing busulfan-based transplantation. After transplantation, 63% of patients in the multicenter analysis had an elevated ferritin, whereas 68% had an elevated LIC. Chelation and phlebotomy were equally effective in reducing post-HSCT iron. These results challenge the use of LIC as the gold standard for iron-related risk stratification in HSCT. Further research into peri-HSCT iron management is necessary in an era of expanding availability of HSCT for NMHD.
- Top Cited Papers
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (19) , 2203-2214
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia
Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-thalassemia (TDT) involves autologous transplantation of hematopoietic stem and progenitor cells transduced with a modified β-globin gene to produce functional adult hemoglobin (Hb) containing βA-T87Q-globin (HbAT87Q). Sixty-three participants with TDT (median age, 17 years [range, 4-35]) received beti-cel in phase 1/2 (n = 22) or phase 3 (n = 41) studies and enrolled in the long-term follow-up LTF-303 study (median follow-up, 5.9 years [range, 2.9-10.1]). Manufacturing refinements in phase 3 increased transduction efficiency, resulting in higher drug product vector copy number and HbAT87Q levels, which translated into higher Hb and transfusion independence (TI) rates than in phase 1/2. TI was achieved by 15 of 22 (68.2%) phase 1/2 participants (median weighted average Hb during TI, 10.2 g/dL) and 37 of 41 (90.2%) of phase 3 participants (median, 11.2 g/dL), and was sustained through last follow-up. Treatment efficacy was similar across ages and TDT genotypes. Among participants achieving TI, 38 of 52 (73%) had discontinued iron chelation at last follow-up, with no increase in liver iron concentration. Markers of ineffective erythropoiesis, including serum transferrin receptor and erythropoietin, improved with restoration of iron homeostasis. Health-related quality-of-life assessment scores showed durable improvements. No malignancies, insertional oncogenesis, or vector-derived replication-competent lentivirus were reported. These findings establish beti-cel as a durable, 1-time therapy that achieves TI, restores iron balance, and improves quality of life, offering a potentially curative treatment option for people with TDT. This trial was registered at www.clinicaltrials.gov as NCT02633943.
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (19) , 2203-2214
Top Cited PapersLong-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia
Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-thalassemia (TDT) involves autologous transplantation of hematopoietic stem and progenitor cells transduced with a modified β-globin gene to produce functional adult hemoglobin (Hb) containing βA-T87Q-globin (HbAT87Q). Sixty-three participants with TDT (median age, 17 years [range, 4-35]) received beti-cel in phase 1/2 (n = 22) or phase 3 (n = 41) studies and enrolled in the long-term follow-up LTF-303 study (median follow-up, 5.9 years [range, 2.9-10.1]). Manufacturing refinements in phase 3 increased transduction efficiency, resulting in higher drug product vector copy number and HbAT87Q levels, which translated into higher Hb and transfusion independence (TI) rates than in phase 1/2. TI was achieved by 15 of 22 (68.2%) phase 1/2 participants (median weighted average Hb during TI, 10.2 g/dL) and 37 of 41 (90.2%) of phase 3 participants (median, 11.2 g/dL), and was sustained through last follow-up. Treatment efficacy was similar across ages and TDT genotypes. Among participants achieving TI, 38 of 52 (73%) had discontinued iron chelation at last follow-up, with no increase in liver iron concentration. Markers of ineffective erythropoiesis, including serum transferrin receptor and erythropoietin, improved with restoration of iron homeostasis. Health-related quality-of-life assessment scores showed durable improvements. No malignancies, insertional oncogenesis, or vector-derived replication-competent lentivirus were reported. These findings establish beti-cel as a durable, 1-time therapy that achieves TI, restores iron balance, and improves quality of life, offering a potentially curative treatment option for people with TDT. This trial was registered at www.clinicaltrials.gov as NCT02633943.
- Open Access
- 15 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 885.e1-885.e14
Factors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL Study
- 15 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 885.e1-885.e14
Open AccessFactors Associated With Pre-donation Health-related Quality-of-Life Among Pediatric Sibling Hematopoietic Cell Donors: A DonorKids QL Study
- Open Access
- 2 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Preemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework
RUNX1 familial platelet disorder (RUNX1-FPD) is associated with a 35% to 50% lifetime risk of hematologic malignancy (HM), and like all germline HM predisposition syndromes, can only be cured with allogeneic hematopoietic stem cell transplantation (HSCT). Current genetic screening techniques allow for early detection of germline predisposition, and consequently, the opportunity for HSCT before overt development of HM (ie, preemptive HSCT). However, there is not yet a consensus on the use of preemptive HSCT for RUNX1-FPD. Described here is the case of an individual with RUNX1-FPD and a family history of HM who underwent preemptive HSCT. We introduce a shared decision-making framework designed to support individuals with RUNX1-FPD, their families, and their multidisciplinary clinical teams in evaluating whether and when to pursue preemptive HSCT versus continued surveillance. The framework reviews key medical factors that influence HSCT timing decisions, including germline and somatic variants, clonal changes over time, familial history of HM, early morphologic or hematologic features, bleeding-related quality of life impacts, and donor availability. The framework also summarizes the major risks and uncertainties potentially associated with preemptive HSCT while highlighting the associated ethical challenges. Together, the case and framework provide a structured, patient-centered approach for navigating the complex clinical decision of preemptive HSCT. Ongoing collaborative efforts to define cytogenetic and clonal changes preceding malignant transformation in RUNX1-FPD will refine the framework and bolster individualized treatment strategies aimed at preventing HM and improving the quality of life of individuals with RUNX1-FPD.
- 2 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Open AccessPreemptive hematopoietic stem cell transplantation in RUNX1 familial platelet disorder: a shared decision-making framework
RUNX1 familial platelet disorder (RUNX1-FPD) is associated with a 35% to 50% lifetime risk of hematologic malignancy (HM), and like all germline HM predisposition syndromes, can only be cured with allogeneic hematopoietic stem cell transplantation (HSCT). Current genetic screening techniques allow for early detection of germline predisposition, and consequently, the opportunity for HSCT before overt development of HM (ie, preemptive HSCT). However, there is not yet a consensus on the use of preemptive HSCT for RUNX1-FPD. Described here is the case of an individual with RUNX1-FPD and a family history of HM who underwent preemptive HSCT. We introduce a shared decision-making framework designed to support individuals with RUNX1-FPD, their families, and their multidisciplinary clinical teams in evaluating whether and when to pursue preemptive HSCT versus continued surveillance. The framework reviews key medical factors that influence HSCT timing decisions, including germline and somatic variants, clonal changes over time, familial history of HM, early morphologic or hematologic features, bleeding-related quality of life impacts, and donor availability. The framework also summarizes the major risks and uncertainties potentially associated with preemptive HSCT while highlighting the associated ethical challenges. Together, the case and framework provide a structured, patient-centered approach for navigating the complex clinical decision of preemptive HSCT. Ongoing collaborative efforts to define cytogenetic and clonal changes preceding malignant transformation in RUNX1-FPD will refine the framework and bolster individualized treatment strategies aimed at preventing HM and improving the quality of life of individuals with RUNX1-FPD.
- 1 April 2026
- Published by Springer Nature
- p. 527-539
Inherited Bone Marrow Failure Syndromes
- Open Access
- 24 March 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (2)
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM
- 24 March 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (2)
Open AccessSystemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM